The need for antiviral therapies for papillomavirus infections is well recognized but the difficulties of reproducing the infectious cycle of papillomaviruses in vitro has hindered our understanding of virus-cell interactions and the regulation of viral gene expression during permissive growth. Recent advances in understanding the temporal expression and function of papillomavirus proteins. has enabled consideration of a targeted approach to papillomavirus chemotherapy and in particular the inhibition of viral replication by targeting the El and E2 proteins. There are in vitro culture systems available for the screening of new chemotherapeutic agents, since significant advances have been made with culture systems which promote epithelial differentiation in vitro. However, to date, there are no published data which show that virions generated in vitro can infect keratinocytes and initiate another round of replication in vitro. In vivo animal models are therefore necessary to assess the efficacy of antivirals in preventing and treating viral infection, particularly for the low-risk genital viruses which are on the whole refractory to culture in vitro. Although papillomaviruses affect a wide variety of hosts in a species-specific manner, the animals most useful for modelling papillomavirus infections include the rabbit, ox, mouse, dog, horse, primate and sheep. The ideal animal model should be widely available, easy to house and handle, be large enough to allow for adequate tissue sampling, develop lesions on anatomical sites comparable with those in human diseases and these lesions should be readily accessible for monitoring and ideally should yield large amounts of infectious virus particles for use in both in vivo and in vitro studies. The relative merits of the various papillomavirus animal models available in relation to these criteria are discussed.
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The papillomaviruses are a large and fascinating group of pathogens infecting skin and internal mucosae, where they induce a range of proliferative lesions ranging from warts to cancer. These viruses are not classified serologically but by nucleotide sequence homology. At present about 75 human papillomavirus (HPV) genotypes have been cloned from clinical biopsies, each with a predilection for a cutaneous or mucosal surface (De Villiers, 1994) . The genotypes infecting the genital tract have received close attention because of the strong association between infection with specific genital HPVsand anogenital cancer, particularly cancer of the uterine cervix (zur Hausen, 1994) . About 28 HPVs regularly or sporadically infect the genital tract and these can be divided roughly into two groups. One group includes those HPVs, mainly types 6 and 11, associated with exophytic condylomata acuminata or true genital warts, found predominandy in the lower genital tract. The other group includes and minor related types, associated with intraepitheliallesions or flat condylomata, particularly of the cervix (zur Hausen, 1994) . These distinctions are not absolute: HPV-16 and -18 can be detected in 1-2% ofgenital warts (Coleman et al., 1994) and HPV-6 can be found in low grade cervical lesions (Anonymous, 1996) . However, the association between infection with HPV-16 or -18 and the risk of subsequently developing cervical cancer is strong enough to warrant the description of HPV-16 and -18 as carcinogens (Anonymous, 1996) . This raises the possibility that intervention in the natural history ofHPV infection in the genital tract, either by prevention of infection or treatment of established disease, would be an effective anticancer strategy.
Although the oncogenic HPVs receive a great deal of attention, disease induced by the low-risk genital viruses is not trivial in terms of morbidity or economic and social costs. Genital warts are the most common viral sexually transmitted disease in the UK and USA (Anonymous, 1989; Becker et al., 1987) . Therapy is generally unsatisfactory with a high frequency of recurrence, and a significant proportion of individuals have lesions which are refractory to treatment (von Krogh, 1996) . Although immunologically based prophylactic and therapeutic strategies are attractive options for papillomavirus-induced disease, there is an increasingly important group of patients with HPV infections who are immunosuppressed, either as a consequence of organ transplantation or human immunodeficiency virus infection (Benton & Arends, 1996) . Not only is infection with both cutaneous and genital HPVs one of the most frequent viral complications in these individuals, but the lesions are persistent and refractory to treatment. In addition there is an increased risk of malignant transformation in these lesions, both in those in whom oncogenic HPVs are detected and in cutaneous lesions induced by the nononcogenic HPVs on sun-exposed surfaces (Stark et al., 1994; Shamanin et al., 1994) . HPV-induced disease in immunosuppressed individuals identifies a clear need for chemotherapy in the form of specific anti-HPV drugs for both topical and systemic treatment. This objective is dependent upon an understanding of the biology of the virus and its interaction with the target cell for infectionthe keratinocyte. The unique replication strategy of papillomaviruses, in which virus replication and keratinocyte differentiation proceed in parallel, with virus assembly confined to terminally differentiating keratinocytes, and the difficulties of reproducing this scenario in vitro, have contributed significantly to the problems of understanding virus-cell interactions and the regulation of viral gene expression during permissive growth.
Infectious cycle of the papillomaviruses
Papillomaviruses exhibit an exquisite tissue tropism. They are strictly epitheliotrophic viruses and have evolved a remarkable replication strategy which depends upon the complete expression of the keratinocyte differentiation programme from stem cell to squame. This absolute dependence upon the squamous epithelial microenvironment was shown first for the cottontail rabbit papillomavirus (CRPVj Kreider & Bartlett, 1981) . In papillomas induced by infection with CRPV; the basal epithelial layers are hyperplastic but viral DNA is difficult to detect. In the upper layers of the stratum spino sum and in the stratum granulosum, virus DNA at high copy number is 382 detectable, although viral capsid antigen and virus particles can be detected only in the extreme superficial differentiated layers of the papilloma. This pattern of replication and dependence upon keratinocyte terminal differentiation for late gene expression has been shown in HPV-6-and HPV-ll-infected genital condylomata and in low grade cervical intra-epithelial neoplasia (CIN; Higgins et al., 1992a) . Viral gene expression during the infectious cycle ofHPV-ll has been analysed by in situ hybridization and immunochemistry using the nude mouse xenograft model of Kreider et al. (1985) , in which HPV-ll-infected foreskin is implanted under the renal capsule. In this model no evidence of viral transcription could be detected until 4 weeks after transplantation, at which time expression from probes spanning the early region, and E4/E5 in particular, is evident (Stoler et al., 1990) . Subsequently, the explants underwent classical. condylomatous transformation over the next 4 weeks; viral DNA replication increased in parallel with epithelial differentiation, being detectable first in the stratum spinosum but with a maximum signal in the stratum granulosum. Transcripts for E6 and E7 were not detected in basal cells but appeared in the parabasallayers at week 6, becoming progressively more abundant with time. Transcripts for L1 and L2 were not detected until week 8, and were confined to the most superficial differentiated cells.
The dependence upon keratinocyte lineage for viral gene expression extends to the target cell for infection. Recently it has been shown (Schmitt et al., 1996) that in the skin of rabbits infected with CRPV; viral gene transcription is detected first in the hair follicle in cells which have some of the characteristics of stem cells (Miller et al., 1993) . If the target cell for infection is indeed a stem cell this does offer an explanation for some aspects of the papillomavirus infectious cycle. There is the interesting phenomenon of the lag phase (which can be weeks or months) between infection and the first evidence of viral gene expression, seen both in the rabbit (Kreider & Bartlett, 1981; Schmitt et al., 1996) and nude mouse xenograft models (Stoler etal., 1990; Sterling etal., 1990) , with anecdotal evidence in man (Oriel, 1971 ). An attractive explanation for this is that the virus infects the stem cell, which is out of cycle in Go' and the 3-4 week delay before viral gene expression is detectable reflects the time required for the stem cell to be recruited into the cycle and for the committed daughter cells to enter the transit cycling population of the epithelium (which includes the basal and parabasal cells), permissive for immediate early viral gene expression.
Latency
Dependence upon a stem cell milieu also offers an explanation for the phenomenon of latency. HPV is frequently present in a latent state in the female genital tract (Toon et al., 1986) . Respiratory papillomatosis is characterized by multiple recurrences interspersed with variable periods of remission. It is generally believed that some of these multiple recurrences reflect activation oflatent infection rather than reinfection (Abramson et al., 1987) , and indeed histologically normal but HPV DNA-positive laryngeal tissues express low abundance transcripts coding for E1 and E2 (Maran et al., 1995) . Similarly, in the CRPV, model a latent infection can be induced (Amella et al., 1994) . Little is known about epidermal or mucosal stem cells but it is clear from other systems, such as the gastric mucosa, that at anyone time the majority of these cells are quiescent and out of the cell-cycle (Winton & Ponder, 1990) . They can be recruited into the cycle either by wounding or as part of the normal regulated self-renewal process of the epithelium. The frequency with which this recruitment occurs is likely to be variable and would depend upon the position of the cell in the stem cell hierarchy. These aspects of papillomavirus biology are poorly understood at present but clearly have implications for antiviral therapies.
Papillomavirus genome organization
The application of molecular cloning and sequencing of the genomes of papillomaviruses has permitted a systematic analysis of the genes encoded by this group of viruses. The DNA of more than 60 genotypes has now been sequenced, and overall there is a high degree of conservation of genome organization (Fig. 1) . The HPV genome can be divided into three domains: a non-coding upstream regulatory region (URR) of approximately 1 kb, an early region with open reading frames (ORPs) E6, E7, E1, E2, E4 and E5, and a late region encoding two genes, L1 (the major capsid protein) and L2 (the minor capsid protein).
Upstream regulatory region
The URR contains the origin (ori) of DNA replication and binding sites for numerous cellular transcription factors including TBP, Sp1, AP1, YY1 and glucocorticoids (O'Connor et al., 1995) .
Early genes
All virus genes are transcribed from the same strand but, despite the apparently simple genetic organization, the actual protein products are complex because of the use of alternative promoters and multiple RNA splicing events (Smotkin et al., 1989; Doorbar et al., 1990; Palermo Dilts et al., 1990; Rohlfs et al., 1991) . The E6 and E7 genes of the HPVs encode proteins which, in the context of the virus life cycle, delay the differentiation programme of the infected keratinocyte permitting viral replication. Inappropriate expression of these genes by the high-risk Antiviral Chemistry& Chemotherapy 8(5) Models for anti-papillomavirus therapy viruses, either temporally or spatially, is associated with neoplastic progression in vivo (Higgins et al., 1992a; Griep et al., 1993) and expression of these ORFs is essential for in vitro transformation ofprimary human keratinocytes by HPV-16 or -18 (Munger et al., 1989; Kaur & McDougall, 1988) . Both E6 and E7 form complexes with cell proteins which playa negative role in regulating cell growth and the fact that some of these interactions are much weaker with the E6 and E7 proteins of the low-risk viruses supports the notion that the oncogenic potential of the high-risk types correlates with the function of these early genes (Crook & Vousden, 1996) . Several proteins are known to form complexes with E7, and to date the most intensively studied of these associations are those with the retinoblastoma gene product Rb, and the associated pocket proteins p107 and p130 (Vousden, 1995) . The mechanism underlying these interactions seems to be the disruption of the association between Rb and the transcription factor E2F. E2F-responsive promoters are a feature of many genes whose expression is central to the regulation of the cell cycle (cdc2, cyclin A, cyclin B and others) and to the regulation of DNA synthesis (thymidine kinase and DNA polymerase) (Crook & Vousden, 1996) . However, during viral replication high-level expression of E7 and E6 is confined to the non-dividing differentiated cells in the superficial layers of the epithelium (Higgins et al., 1992b; Stoler et al., 1989) . Elegant studies using organotypic cultures indicate that the function of E7 in these cells is to induce cellular DNA synthesis, thus permitting viral DNA replication (Cheng et al., 1995) . Rb binding is not essential for papilloma formation, at least in the CRPV system, since viral DNA in which the Rb-binding domain had been deleted still induce papilloma formation in infected animals (Defeo-Jones et al., 1993) The interactions between the E6 proteins of the highrisk HPVs and p53 have been intensively investigated (Vousden, 1995) , and there is general agreement that E6 from high-risk HPVs binds to and degrades p53 but that the E6 of low-risk HPVs is relatively inefficient in this process. The inhibition of p53 function so engendered, particularly the induction of apoptosis, is probably critical for neoplastic progression. Elegant studies in transgenic mouse models show that E7 expression alone results in apoptosis of differentiated epithelial cells, but expression ofE6 together with E7 abrogates this effect (Pan & Griep, 1994 , 1995 . One might speculate, in view of these data, that therapies for high-risk HPVs designed to target E6 alone might be effective since continued expression of E7 could induce apoptosis.
The functions of the E5 gene product are imperfectly understood. This ORF encodes a small, intensely hydrophobic protein localized predominantly within the membranes of the Golgi and endoplasmic reticulum (Burkhardt et al., 1989; Conrad et al., 1993) . The E5 gene of bovine papillomavirus (BPV) is a major transforming gene and probably exerts its effect via the interaction with receptors for EGF and PDGF (Banks & Madashewski, 1996) . The E5 proteins of both HPV and BPV complex with the 16 kDa component of the vacuolar H+-ATPase complex, inhibiting acidification of the endosome with the 384 consequent retention of non-degraded EGF-R and upregulation of receptor density (Goldstein et al., 1991 (Goldstein et al., , 1992 . The interaction with the PDGF-R by BPV E5 is different; this is a direct activation by E5 of the PDGFr eceptor (Petti & DiMaio, 1994) . There are undoubtedly other functions of E5, and there are preliminary data to suggest that this molecule may influence antigen processing (FV Cromme, Free University Hospital, Amsterdam, The Netherlands, personal communication). The E4 gene encodes proteins which appear late in the life cycle (Doorbar et al., 1986) . The functions of this protein are not clear, although recent studies show that it binds a member of the DEAD box family of proteins (Doorbar et al.,1996) .
Late genes
The L1 and L2 genes encode the major and minor capsid proteins, respectively, and expression of these genes is absolutely dependent upon keratinocyte terminal differentiation (Sterling et al., 1990) . The regulation of late gene expression is poorly understood but involves both transcriptional (Hummel et al., 1992) and post-transcriptional mechanisms (Dietrich-Goetz et al., 1997) .
PapillomavirU5 replication
A potential target for antivirals to HPV is inhibition of viral replication. Two viral proteins, E1 and E2, have been shown to be essential and sufficient for the initiation of viral replication in cells in monolayer culture . The ability ofBPV-1 to infect mouse C127 cells, and to generate transformed cells carrying stably replicating copies ofBPV DNA (Dvoretzky et al., 1980) , permitted the study ofBPV replication by mutational analysis and identified the E1 ORF as essential for the maintenance of episomal DNA (Sarver et al., 1984; Lusky & Botchan, 1985) . The BPV E1 protein has been extensively characterized and shown to be a 68-72 kDa phosphoprotein containing intrinsic ATPase, helicase and specific DNA-binding activity Wilson & Ludes Meyers, 1991; Yang etal., 1991; Seo etal., 1993a) . The E1 protein of the papillomaviruses is highly conserved within virus types and is absolutely required for viral replication. Numerous studies have shown that the E2 protein is the major papillomavirus transcriptional regulator (Thierry, 1996) . Initial observations that established an essential role for BPV E2 in viral DNA replication attributed this requirement to its function as a transcriptional inducer of viral early gene expression including expression ofE1 (DiMaio & Settleman, 1988; Rabson et al., 1986) . However, transient replication assays have shown that the requirement of BPV E2 for origin-dependent replication is independent of its role as a transcriptional activator of other genes . The E2 protein performs its regulatory roles through binding as a dimer to a specific palindromic sequence repeated several times in the URR and found in all papillomavirus types so far sequenced. The crystal structure of the C-terminal domain of E2 involved in Antiviral Chemistry & Chemotherapy 8(5) Models for anti-papillomavirus therapy dimerization and DNA binding has been resolved (Hegde et al., 1992) , providing an opportunity for the design of inhibitors of these interactions and the potential for inhibition ofviral transcription and replication. In addition to the functions of E1 and E2 described, there is evidence that both proteins are involved in recruiting cellular replication factors (Li & Botchan, 1993; BonneAndrea et al., 1995; Park et al., 1994) . Thus it is clear that E1 and E2 have essential roles in viral DNA replication and are involved in numerous interactions that could be targeted by antiviral drugs.
£1 and £2 are essential for viral DNA replication
Transient replication studies have revealed essential roles for £1 and E2 in viral DNA replication. These studies involve cotransfection of plasmids containing the BPV E1 and E2 ORFs under strong heterogeneous promoters into mammalian cell lines, along with a plasmid containing the papillomavirus URR within which the origin of replication is found . Replication of the URR-containing plasmid was shown to be dependent on the expression ofE1 and E2. However, high concentrations ofE1 alone sustain transient DNA replication at a low level (Gopalakrishnan & Khan, 1994) , although the presence of E2 greatly enhances DNA replication and E2 was shown to be indispensable at limiting E1 concentrations . Similar experiments have indicated a requirement for HPV E1 and E2 gene products in the replication of HPV origin-containing plasmids (Chiang et al., 1992; Del Vecchio etal., 1992; Sverdrup & Khan, 1994) . In addition, the E1 and E2 proteins and replication origins from several papillomaviruses can function together and are interchangeable (Chiang et al., 1992) . This observation suggests that an antiviral compound active against a particular viral type may well be active against other types and may be useful in treatment for a range of HPV-induced diseases. A drug screening assay based on the transient replication assay has recently been set up (Plumpton et al., 1995) . The screen employs a secreted reporter assay in which the activity of alkaline phosphatase in the cell supernatant gives a rapid measure of DNA replication. This assay has enabled high throughput screening for inhibitors of E1fE2-dependent HPV DNA replication.
£1 and £2 mechanism of action
The mechanism of E1 and E2 action has still to be completely resolved. It is known that E2 forms a heteromeric complex with E1 in solution (Mohr et al., 1990; Lusky & Fontane, 1991; Blitz & Laimins, 1991) . It is believed that the E2 protein directs the E1-E2 complex to the origin of replication via the high affinity E2-binding sites which flank the origin, whilst stabilizing E1 in a conformation that facilitates origin recognition. Once there, E1 binds to a weaker site (an AT-rich inverted repeat) and unwinds the DNA bi-directionallyutilizing the hydrolysis ofATP as an energy source Lusky et al., 1993; Seo et al., 1993b) . It has been determined that BPV-l E2 associates transiently with El during assembly of the initiation complex, but is absent in the subsequent replication-competent complex that contains multimers of DNA-associated El molecules (Lusky et al., 1994) . The intracellular ratios of El and E2 may be an important controlling factor in the status of viral DNA replication.
The important role in viral DNA replication played by the interaction between El and E2 has led to an extensive analysis of the mechanism of association between the two proteins. The domains of both the El and E2 proteins necessary for complex formation have been investigated in attempts to discover the nature of the association. Using an extensive set of mutant £2 proteins, two widely separable regions of the E2 protein have been identified which are essential for binding to El (Piccini et al., 1995) . Investigations of the sites on El necessary for interaction with E2 have yielded conflicting results. A number of studies have identified the C terminus of El as being necessary and sufficient for binding to E2 (Lusky & Fontane, 1991; Sarafi & McBride, 1995; Muller & Sapp, 1996) , whilst other studies suggest the N terminus of El is essential (Benson & Howley, 1995; Thorner et al., 1993) . In addition, temperature modulation effects on the EI-E2 association may reflect the existence of different El conformational states, each with its own E2-binding characteristics and contributary domains. Whether differences observed in these studies are due to different experimental strategies or reflect intrinsic differences in the El and E2 proteins of the various papillomaviruses has yet to be determined. Information of this kind is vital in the search for potential therapeutic compounds directed towards the inhibition of the El-E2 association.
In vitro culture systems
The absolute dependence upon keratinocyte differentiation for vegetative viral growth is the chief obstacle in the development of in vitro systems for the assay of antivirals for HPY. In vitro systems which permit serial passage of keratinocytes without fibroblast overgrowth were described in a seminal series of experiments (Rheinwald & Green, 1975) . In these submerged culture systems the keratinocyte maintains a proliferative wound phenotype and eventually undergoes replicative senescence. Keratinocyte differentiation markers are not expressed in these systems and they are not permissive for vegetative viral growth. Infection of such monolayer cultures with HPV virions has been disappointing, with transient replication of episomes only and rapid loss of HPV DNA from the cells (LaPorta & Taichman, 1982; Mungal et al., 1992) .
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Transfection of primary genital keratinocytes with cloned DNA from the oncogenic HPVs together with a selectable marker has, until recently, resulted in the derivation of immortal lines in which viral DNA is integrated, making such lines uninformative for studies on episomal replication. Cell lines in which HPV-16 (Stanley et al., 1989) or HPV-31b (Bedell et al., 1991) are maintained as the episome have been derived as rare events after culture of low-grade intra-epithelial lesions.
Since the infectious cycle of the papillomaviruses is absolutely dependent upon the regulated expression of the keratinocyte from stem cell to differentiated squame, in vitro systems permissive for HPV must mimic the environment that supports keratinocyte differentiation. The regulation of this programme is extremely complex but depends very substantially on signals from the subepithelial dermis or stroma (Leary et al., 1992) . Culture systems which partially reproduce this connective tissue matrix have been developed and, in essence, all these systems consist of a collagen matrix seeded with fibroblasts of human (Bell et al., 1979) or murine origin (Kopan et al., 1987) . Keratinocytes are seeded onto these matrices in submerged culture and when the keratinocyte lawn is confluent the collagen-keratinocyte sandwich is raised by placing it on an inert support, usually a stainless steel grid, so that the keratinocyte layer is at the air-liquid interface. In such organotypic 'raft' cultures the keratinocytes stratify and undergo much of the differentiation programme, with the expression of differentiation-specific keratins and molecules such as fJ.1aggrin and loricrin (Kopan et al., 1987) . Immortal keratinocyte lines transformed by HPV-16 or -18 in which the viral DNA sequences are integrated stratify but differentiate incompletely in raft culture, exhibiting a morphology comparable to high-grade CIN or vaginal intra-epithelial neoplasia (YIN; McCance et al., 1988; Merrick et al., 1992) . Immortal lines containing HPV as the episome, W12 or CIN 612, stratify and differentiate in raft culture and in situ hybridization shows that viral DNA amplification occurs in the upper epithelial layers (Bedell et al., 1991; Stanley, 1994) . Exposure of these cultures to activators of protein kinase C such as the phorbol ester tetradecanoylphorbol-13-acetate (TPA) results in the induction of capsid protein synthesis and the assembly of virions in the superficial cells of the epithelium (Meyers et al., 1992a) . Recently it has been shown (Frattini et al., 1996) that primary human foreskin keratinocytes, lipofected with religated HPV-31b genomes cloned from the CIN 612 line, can stably maintain the viral episome at about 50 copies per cell. Furthermore, these cells in raft culture are permissive for vegetative viral growth in the absence ofTPA treatment. This is a major advance in the study of papillomavirus biology, with the opportunity for analysis of both papillomavirus gene function during the vegetative life cycle, and the downstream consequences of intervening in viral replication. These systems represent powerful tools for the screening of novel antiviral compounds against the high-risk viruses. This is a significant development, but to date only the high-risk transforming viruses have been used successfully in these systems and it would seem that the ability of the oncogenic HPVs to override the mechanisms of cellular senescence and immortalize cells is central to the success of these models. However, permissive growth of the lowrisk viruses can be achieved in organotypic culture if explants of condylomata containing HPV-ll are used to initiate the cultures (Dollard et al, 1992) . Stratification and differentiation in these systems is exquisitely dependent upon the source of the fibroblasts embedded in the collagen matrix. Matrices seeded with human dermal fibroblasts do not support viral DNA amplification, late gene expression or virion assembly but matrices seeded with the A31 3T3 strain of mouse fibroblasts support keratinocyte differentiation and are permissive for viral growth. This dependence upon specific fibroblast populations in the matrix for late gene expression has also been shown for the W12 line (Stanley, 1994) . Although organotypic culture systems mimic quite faithfully the transit amplifying and differentiated populations of squamous epithelium, and submerged cultures express the wound keratinocyte phenotype, neither culture system sustains stem cells and to date there are no published data which show that virions generated in vitro can infect keratinocytes and initiate another round of replication in vitro. In vivo animal models are therefore necessary to assess the efficacy of antivirals in preventing and treating virus infection, particularly for the low-risk genital viruses which, on the whole, are refractory to culture in vitro.
Animal models
There is, understandably, a move toward reducing the number of animals used in experimental science. In the field of papillomavirus research, a large amount of information has been obtained without recourse to animal models, and advances in molecular biology have been critical in the elucidation ofviral gene function. However, at present there remains a need for animal models of papillomavirus-associated disease in order to solve problems which are difficult to approach by purely cellular and molecular means. For the testing of antiviral agents, a system capable of supporting the complete cycle of viral infection and vegetative growth, and also one physiologically and pharmacologically relevant to humans, is required.
Requirements of an animal model
In general, an effective animal model should resemble the biology of the comparable human disease as closely as Antiviral Chemistry & Chemotherapy 8(5) Models for anli-papillomavirus therapy possible, although other more specific criteria have been proposed by which the suitability of an animal system may be judged. Any model should allow rapid, inexpensive induction of the lesion with a minimum of experimental manipulation. The animal should be widely available, bear multiple offspring, suit modern animal housing fa-cilities, be easily handled and be free of specific import and export restrictions, such as those affecting endangered species. The animal should be large enough to allow sufficient tissue biopsies to be taken for multiple techniques such as cell culture and histological studies (Leader & Padgett, 1980; Sundberg, 1987) . A short latency period before the appearance of the primary lesion would be advantageous, as would the development of neoplastic progression in a reasonable proportion of the lesions, although this is less relevant in investigations of anogenital warts than it is with cancer (Brandsma, 1994) . The animal should develop lesions on anatomical sites comparable with those in human diseases, and these lesions should be readily accessible for monitoring. Ideally the system should yield large amounts of infectious virus particles for use in both in vivo and in vitro studies. However, the ability to use recombinant DNA as a source of infection may circumvent this requirement to some extent, depending on which part of the viral life cycle is being studied. There is a wide documented range of animals infected by papillomaviruses. These include the domestic cat (Egberink et al., 1992) , lion (Sundberg et al., 1996) , elk (Eriksson et al., 1988) , chaffinch (Moreno Lopez et al., 1984) and coyote , although only a few have been employed as models for HPV-associated diseases. The main candidates for papillomavirus research are outlined below.
Rodent models
Clearly, for reasons of economy and convenience, it would be useful to have a mouse model for papillomavirus infection. A papillomavirus (MnPV) has been isolated from the multimammate mouse Mastomys natalensis (Muller & Gissmann, 1978) . This animal has been shown to carry endogenous papillomavirus genomes which can be reactivated by mechanical irritation (Siegsmund et al, 1991) , resulting in papilloma formation and virion production. Extrachromosomal papillomavirus genomes can be found in a variety of tissues, with an increase in copy number with age, leading to tumours at around 1 year (Amtmann et al., 1984) . The genome has been sequenced, and has some similarity to that of CRPV and some of the cutaneous HPVs (Tan etal, 1994) . A papillomavirus (MmPV) from the European harvest mouse Min"omys minutus has been cloned and characterized (O'Banion et al, 1988a) . This virus has been associated with a variety of tumours including papillomas and sebaceous carcinomas and has homology with rabbit oral papillomavirus (ROPV), MnPV and HPV-1a (O'Banion et al., 1988b) . Horizontal transmission was successful, although it was not possible to transmit the virus to inbred strains of laboratory mice .
A further mouse model for papillomavirus infection utilizes the papillomas induced by UV irradiation of the hairless mouse strain Mus musculus HRNSkh. Papillomavirus DNA sequences have been detected in papillomas, carcinomas in situ and squamous cell carcinomas, as well as in tumours induced by topical agents . No virus particles were seen in the lesions, and papillomavirus group-specific antigens were not detected. Restriction enzyme digests indicated that this papillomavirus was different from MnPV. Tumour extracts containing papillomavirus DNA increased the susceptibility of inoculated hairless mice to UV-induced tumorigenesis . This system has been proposed as a useful model with which to study the association between UV light, papillomaviruses and tumour formation.
Transgenic mouse models
Various rodent-based models have been used which do not rely on rodent papillomaviruses. Artificial papillomavirus 'infections' have been created by using transgenic mice carrying the BPV-1 genome (Lacey et al., 1986) . Since then a variety of mice transgenic for human papillomavirus genes have been developed, enabling studies on tissue specificity (Cid et al., 1993) , epidermal neoplasia (Greenhalgh et al., 1994; Lambert et al., 1993) , dysplasia and hyperplasia of genital epithelia (Sasagawa et al., 1994) , immunological responses to viral oncoproteins (Frazer et al., 1995) and hormonal cofactors in carcinogenesis (Arbeit et al., 1996) .
Xenograft models
Xenograft systems which reproduce the environment for epithelial differentiation have provided seminal data on viral gene expression during the infectious cycle and are valuable for the assay of antivirals. The prototype for these is the nude mouse xenograft model developed by Kreider et al. (1985) . In this system, small chips of human skin or mucosa are incubated with the Hershey strain of HPV-ll for 1-2 h in vitro and are then implanted under the renal capsule of the nude mouse. After 6-8 weeks condylomatous transformation of the grafts occurs, with epithelial cysts containing large numbers of virions which can be purified and serially passaged . Experimental infection and production of HPV-1 has also been achieved with the renal capsule xenograft model ) and grafting of skin fragments from patients with epidennodysplasia verruciformis (EV) resulted in the expression of EV-associated HPV-5, -8, -9, 388 -12 and -36 within the cysts (Majewski et al., 1994) . The renal capsule transplantation model requires formidable technical expertise; a more tractable system (Sterling et al., 1990 ) is that in which W12 cells are transplanted into a skin pocket on the flank of the nude mouse using a transplantation technique which permits epithelial reformation (Hammond et al., 1987) . This results in the expression by W12 cells of the complete keratinocyte differentiation programme and the assembly of HPV-16 virions in the superficial layers of the epithelium so formed (Sterling et al., 1990 (Sterling et al., , 1993 .
Nude mice, although T cell-depleted, are not natural killer cell-or macrophage-depleted, and the latter have considerable cytotoxic capacity resulting in relatively low graft success in the mice. Severe combined immunodeficient (SCID) mice are lymphoid-depleted and HPV-llinfected foreskin grafts under the renal capsule in SCID mice show enhanced graft take and size (Bonnez et al., 1993) . Furthermore, such grafts will grow in the subcutis and peritoneum. HPV-6-and HPV-ll-infected biopsies from genital and laryngeal warts, grafted onto SCID mice using the transplantation chamber technique, resulted in growth of the grafts and expression ofviral capsid proteins, although these grafts could not be serially passaged (Sexton et al., 1995) . A promising system was described by Brandsma et al. (1995) , in which human foreskin inoculated with HPV-16 DNA genomes by gene gun delivery was subsequently grafted in a subcutaneous pocket onto the flank of SCID mice. A papillomatous lesion in which viral capsid proteins were expressed developed on the grafted skin. This system generates easily accessible macroscopic papillomas and provides a useful model of developing lesions in which antiviral therapies can be tested.
Some of these models are limited by the difficulties of monitoring lesion progression, such as with grafts located under the renal capsule, within the peritoneum or in the subcutis. Other limitations include low levels of virion production, or a dependence on cell lines rather than clinical isolates as an initial virus source, although the ability to use naked recombinant viral DNA rather than intact virus makes the latter point less restrictive.
Rabbit papillomaviruses

Cottontail rabbit papilloma virus
CRPV is a naturally occurring infection causing cutaneous papillomas, some of which progress to squamous cell carcinomas in the natural host Sylvilagus floridanus (Rous & Beard, 1935) . CRPV has been studied extensively since its description by Shope (1933) . The natural host, the cottontail rabbit, is not easily available and does not do well in captivity but the ability to transmit CRPV to domestic rabbits (OIJctolagus cunniculus) has increased the utility of this system. In the domestic rabbit, malignant conversion occurs at high frequency (Syverton, 1952) , although virion production is insignificant (Wettstein & Stevens, 1982) .
Evaluation of therapeutic agents in the CRPVmodel
CRPV infection in domestic rabbits has been used as a model system for the testing of possible therapeutic agents. Since the lesions develop on the dorsal skin, they are easily visualized and can be counted and measured directly to allow evaluation of the efficacy of therapeutic agents. Ostrow et al. (1992) used domestic rabbits infected with CRPV and tested the effects of ribavirin on the development of the resulting cutaneous papillomas. Daily intradermal injection ofribavirin resulted in a dose-dependent reduction in the number of warts, reduction in wart mass and prolongation of the time until first wart appearance. Domestic rabbits infected with CRPV were used to evaluate the efficacy of topical podofilox therapy on papillomas . Podofilox treatments were found to inhibit strongly papilloma growth, with CRPV DNA being undetectable by PCR or Southern blots of tissue from cured sites. Another putative topical therapeutic agent, the cobalt-containing complex CTC-96, was found to cause earlier appearance of tumours, at a greater number of sites, than with the control group (Ostrow et al., 1994) . Photodynamic therapy has been tested in the CRPVdomestic rabbit system. Early trials with a haematoporphyrin derivative demonstrated marked regression of tumours (Shikowitz et al., 1986) without recurrence and with disappearance of CRPV DNA from regressed lesions (Shikowitz et al., 1988) . More recent work using m-tetra-(hydroxyphenyl)chlorin , achieved a 75% cure rate with papillomas under 100 mm/ in area. A similar model was used to evaluate protoporphyrin IX (PPIX), produced by metabolism of I)-aminolaevulinic acid (ALA; Lofgren et al., 1995) , achieving a 3 month cure rate of 82% with papillomas below a certain size. This type of therapy has the potential to damage adjacent tissues; the larynx of normal rabbits has been used to investigate the distribution of photoactive agents and the resulting tissue damage and healing after photodynamic therapy (Kleemann et al, 1996) .
These experiments demonstrate clearly the ability of the different CRPV-based systems to generate lesions with easily quantified progression and regression. Additionally the lesions are large enough to provide sufficient tissues for histological and molecular studies, and useful amounts of blood can be withdrawn without harming the animal. The flexibility of the CRPV system is evident from work which demonstrated its ability to model latent papillomavirus infections. Low concentrations of a viral inoculum resulted in delayed and reduced efficiency of wart production. Low levels of viral DNA could be Antiviral Chemistry & Chemotherapy8 (5) Models for onfi-popillomovirus therapy detected in sites where papillomas did not form, and the latent virus could be reactivated by mechanical irritation of the skin (Amella et al., 1994) . This system could be used to study mechanisms of viral activation and provides a means for evaluating therapies aimed at preventing viral activation or eliminating latent virus.
CRPVin vitro models
An in vitro system, based on infection of a cottontail rabbit epidermal cell line with CRPV, was able to yield CRPV-specific transcripts, providing a possible model for analysis of the early events of virus infection (Angell et al., 1992) , although productive infection was not achieved. A further development of the rabbit system has been the production of a neoplastic cell line arising from a CRPVinduced lesion. The papillomavirus-induced squamous cell carcinoma VX-2 cell line has been used in rabbits to investigate perilesional interleukin 2 (IL-2) as a possible treatment for squamous cell carcinoma (Carroll et al., 1995) . Tumour growth was inhibited in animals receiving IL-2, although lower doses of IL-2 tended to enhance tumour growth. These findings suggested that high dose recombinant IL-2 has a potential role in tumour therapy. The VX-2 carcinoma has also been used to investigate the effect of oxygen radicals produced locally by arterial administration ofxanthine oxidase and venous administration of hypoxanthine (Yoshikawa et al., 1995) . Significant suppression of tumour growth was reported, indicating the potential utility of oxygen radical-based therapies.
The CRPV genome has been cloned and sequenced (Giri et al., 1985) which, combined with an efficient means for inoculating rabbits with DNA (Brandsma et al., 1991) , has allowed the effects of specific mutations to be studied by infecting rabbits with molecular clones (Brandsma et al., 1991; Wu et al., 1994) . Frameshift mutations were made in the E1 and E2 regulatory genes, and the resulting mutant CRPV genomes failed to induce papillomas in domestic rabbits. This system has demonstrated the requirement for E1, E2, E6, E7 and L1 genes for papilloma formation, although the L1 gene is dispensable for transformation (Meyers et al., 1992b; Nasseri et al., 1989 ). An interesting demonstration of the potential for ribozyme-based therapies has been performed using a CRPV system (Wisotzkey et al., 1993) . A plasmid was designed which contained a gene for a hammerhead ribozyme which specifically cleaved CRPV E7 transcripts in vitro, suggesting that these genes may have potential as targets for therapeutic intervention.
Transgenic rabbit model
To overcome some of the difficulties involved in infecting domestic rabbits with CRPV, transgenic rabbits have been created which cany either CRPV DNA alone, or both CRPV DNA and EJ-ras (Peng et al, 1993) . The rabbits carrying CRPV DNA alone developed extensive skin papillomas at an early age, with transcripts of CRPV DNA found only in skin or papillomas. The rabbits transgenic for both CRPV DNA and EJ-mssuffered extensive cutaneous squamous cell carcinomas, also at an early age. It was proposed that extensive methylation of the CRPV genome, especially in the URR, may be a factor controlling tissue-specific expression of the genome (Peng et al., 1995) . These models may provide clues as to the factors affecting the tissue specificity of papillomaviruses. A better understanding of the mechanisms controlling genome expression may provide clues for the rational design of therapies.
The main limitations of the CRPV system include the limited availability of the natural host, the non-productive infections in the domestic rabbit and the fact that the virus affects haired skin rather than mucosal surfaces. A further virus, ROPV, infects domestic rabbits causing oral papillomas (not transmissible to the genital tract), with abundant virion production (Sundberg et al., 1985) . The genome has been cloned and partially sequenced (O'Banion et al., 1988b) , showing similarities with CRPV, HPV-la, HPV-16 and BPV-5. Rabbit tongue tissues have been incubated with ROPV and placed subrenally into athymic mice, producing stocks of infectious ROPV particles (Christensen et al., 1996) . As a mucosal animal papillomavirus, ROPV clearly has potential as an experimental system for modelling human mucosal papillomavirus infections.
Canine papillomavirus
The existence of transmissible warts in the dog was noted almost 100 years ago (Penberthy, 1898) . Since then, experimental transmission by cell-free extracts (Chambers & Evans, 1959) , the histological and electron microscopic appearances (Watrach, 1969) and sequencing of the viral genome (Delius et al., 1994) have confirmed the involvement of a papillomavirus. Papillomas have been identified in the oral cavity (including buccal mucosa, tongue and soft palate), skin, conjunctiva, penis and vulva (Belkin, 1979; Bonney et al., 1980; Hare & Howard, 1977; Sansom et al., 1996; Sundberg et al., 1984; Tokita & Konishi, 1975) . The cutaneous lesions include both squamous papillomas (Campbell et al., 1988; Watrach et al., 1969) , cutaneous inverted papillomas (Campbell et al., 1988; Shimada et al., 1993) and squamous cell carcinomas (Watrach et al., 1970) . Squamous cell carcinomas have been associated with the use of a live canine oral papillomavirus (COPV) vaccine (Bregman et al., 1987; Ghim etal., 1995) . The canine 'pigmented epidermal nevus' is associated with a papillomavirus, and some parallels have been drawn with human EV (Nagata et al., 1995) . It is thought that there are several types of canine papillomavirus 390 (Campbell et al., 1988; Delius et al., 1994) , each having a different tissue tropism which may be expanded by natural or iatrogenic immunosuppression. This theory is supported by the recent finding of a new papillornavirus isolated from cutaneous papules in an immunosuppressed dog (Le Net et al., 1997) . Preliminary data indicate that the virus shares only 70% nucleotide similarity with COpy in the Ll ORF.
Experimental studies of COpy infection reported incubation periods of between 3 and 8 weeks, with 69% developing within 4-5 weeks. The longest wart duration was 21 weeks, with the modal duration being 4-8 weeks (Chambers & Evans, 1959) . The time of regression appeared to be related to concentration of viral inoculum, with delayed regression in dogs inoculated with greater dilutions. The dog has been used to model the side-effects on the larynx of photodynamic therapy . Recent work has concentrated on using the canine papillomavirus model to evaluate both formalin-inactivated virus and recombinant viral capsid (Ll.) proteins for use as vaccines (Bell et al., 1994; Ghim et al., 1995; Suzich et al., 1995) .
There are disadvantages associated with the use of dogs, including their relatively high purchase and maintenance costs, although not when compared with other systems such as the bovine model. However, the canine model has several advantages over other animal models. The dog is a standard laboratory animal, and much is known about its physiology. A broad range of canine immunological reagents is available with which to characterize cellular and humoral events. Additionally, COPY is a mucosal papillomavirus, with obvious similarities to the important mucosal papillomavirus infections of humans. The lesions are easily induced and monitored, yield high titres of infectious virions (Chambers & Evans, 1959; Konishi et al., 1972) and the animals suffer no significant adverse effects, recovering completely with immunity to further infection.
Bovine papillomaviruses
Six types of bovine papillomaviruses have been characterized. BPV-l, -2 and -5 (Campo et al., 1981; Chen et al., 1982; Lancaster, 1979) cause fibropapillomas, in which there is a marked dermal proliferative component. Fibropapillomas are found on the skin, rumen, omasum and anogenital squamous epithelium. Each virus type is associated with certain anatomical sites. These fibropapillomas are distinct from the important papillornavirusassociated human lesions and do not undergo malignant progression. Despite their dissimilarities with HPV-related disease, these bovine viruses have proved to be important model systems.
Because of their large viral content, bovine fibropapillomas have been used to quantify some of the health risks associated with carbon dioxide laser therapy, used to vapourize warts. Vapour collected from bovine fibropapillomas after laser treatment was found to contain intact BPV DNA, with intact viral DNA also being liberated from laser-treated human plantar warts, creating potentially infectious aerosols (Garden et al., 1988) . This work was extended to investigate the risks associated with electrocoagulation and laser therapy, using both human plantar warts and bovine fibropapillomas to recover viral DNA in aerosols (Sawchuk et al., 1989) . Bioassays revealed that both treatment modalities liberated infectious papillomavirus DNA, most ofwhich could be filtered by a surgical mask.
The high viral content of bovine fibropapillomas has allowed large amounts of virus to be obtained for use in vitro. BPV has the ability to transform cultured cells (DiMaio, 1991; Nakabayashi et al., 1984) and can induce tumours in hamsters (Cheville, 1966; Robl & Olson, 1968) . Cloning and characterization of the viral genomes (Campo & Coggins, 1982; Chen etal., 1982; Coggins etal., 1985) has enabled gene functions to be investigated (Androphy et al., 1985; Jareborg et al., 1992) and in vitro mutagenesis studies have revealed much about the molecular biology of BPV-1 (DiMaio, 1991; Lentz et al., 1993) . Additionally, there is good evidence that BPV-1 and BPV-2 can remain as latent infections, being reactivated by immunosuppression or physical trauma to cause cutaneous papillomas or urinary bladder cancer (Campo et al., 1994) . This finding obviously raises the possibility that this system could act as a more general model of papillomavirus latency. BPV-3, -4 and -6 (Jarrett et a/., 1984; Patel et al., 1987; Pfister et al., 1979) cause true epithelial papillomas on the skin, upper alimentary tract and udder, respectively. The papillomas caused by BPV-4 are of interest since they affect mucosal epithelium and can progress to squamous cell carcinoma, with obvious parallels with the human mucosal papillomaviruses. BPV-4 therefore provides an important model of mucosal papillomavirus infections, with the ability to create and monitor lesions in the oral cavity. Unfortunately it is difficult to monitor the progression of these tumours in the upper alimentary tract, and there are mechanistic differences in the oncogenic process itself, since BPV-4 genes do not need to be present continually for malignant progression to occur (Campo, 1987) . Cattle are obviously expensive and inconvenient as a model system for papillomavirus studies, but have nevertheless provided important data in studies on vaccination and potential therapies (Jarrett et al., 1990) .
Despite the large size and inconvenient husbandry requirements of cattle, they have been used in various therapeutic trials. Local injection of IL-2 as a therapy for Antiviral Chemistry & Chemotherapy 8(5) Models for anti-papillomavirus therapy papillomas and carcinomas has been tested in a bovine model (Hill et al., 1994a ). An effect on tumour load was observed in over 80% of treated animals, with complete regression in some. Regression was not restricted to the injected tumours in most cases. The same model was used to test the efficacy of intra-lesional injectionof live bacillus Calmette-Guerin (BCG), causing total regression of all of six carcinomas and limited regression of advanced papillomas (Hill et al., 1994b) .
Most therapeutic studies using BPV have utilized in vitro systems rather than a whole animal approach. The E2 gene product has been suggested as a target for antivirals and the potential therapeutic action of antisense oligonucleotides complementary to E2 mRNA has been assessed (Cowsert et al., 1993) . E2-dependent transactivation and viral focus formation was reduced in a sequencespecific and concentration-dependent manner by antisense oligonucleotides complementary to the mRNA cap region and the translation initiation region for the full-length E2 transactivator region. An antisense oligonucletoide to the translation initiation region of HPV-6 and HPV-ll E2 mRNA was able to inhibit E2-dependent transactivation, suggesting that antisense oligonucleotides may have a role in the treatment of genital warts.
It is clear that BPV models have made very important contributions in the field of papillomavirus research. For whole animal studies of potential therapeutic strategies however, cattle remain a less than ideal system due to the expense and inconvenience of the husbandry requirements.
Ovine papillornavirus
Papillomas occur occasionally on the limbs, ears and muzzle of sheep, and papillomavirus-like particles have been demonstrated by electron microscopy (Gibbs et al., 1975; Vanselow & Spradbrow, 1983; Vanselow et al., 1982) . DNA extracted from ovine papillomas has been shown to hybridize to HPV-16 DNA under conditions of low stringency (Hayward et al., 1993) . The demonstration by DNA hybridization of papillomavirus-related sequences in squamous cell carcinomas of the perineum of sheep indicates a possible role for papillomaviruses in the development of these lesions (Tilbrook et al., 1992) . Papillomavirus DNA has also been detected in aural precancerous lesions of sheep (Trenfield et al., 1990) , with a restriction digest pattern close to that of BPV-2. It is thought that there may be a progression of papillomas to squamous cell carcinoma, with exposure to sunlight playing a role (Tilbrook et al., 1992; Vanselow et al., 1982) . Ovine warts can be transmitted experimentally to other sheep, and can also induce fibromas in hamsters (Gibbs et al., 1975) . Ovine papillomavirus has been classified into supergroup C along with the other ungulate fibropapillomaviruses , although there may be more than one ovine papillomavirus, since both fibropapillomas and squamous papillomas have been described (Gibbs et al., 1975; Hayward et al., 1993) . When considering their potential as an animal model of papillomavirus-associated disease, the smaller size of sheep gives them an economic and practical advantage over cattle and horses. Against this must be balanced the large amount of information already available for the bovine models, together with the availability of better-characterized alternatives such as the rabbit and dog.
Equine papillomas
Papillomas are moderately common m the horse (Sundberg et al., 1977) and can be transmitted experimentally (Hamada et al, 1990) . Experimental transmission caused papillomas to appear within 19-26 days of infection, reaching maximum size by 39-54 days. The papillomas are often found on the penis or vulva. Squamous cell carcinomas are common in the horse and are found in sites similar to those of papillomas. Although viral antigens were detected in genital papillomas, they were not found in genital squamous cell carcinomas . Papillomavirus antigens have been detected in papillomas contiguous with invasive equine penile squamous cell carcinoma (Sundberg, 1987 ).
An equine cutaneous papillomavirus has been cloned and characterized (O'Banion et al., 1986) and the difference in restriction patterns between the cutaneous isolate and one from a penile papilloma indicates the existence of more than one virus type. Equine sarcoids, which have both a fibrous and epithelial proliferative component, have been found to contain DNA with restriction enzyme profiles characteristic of BPV-l or BPV-2 (Angelos et al., 1991) , indicating that these viruses or close relatives are involved in the pathogenesis of equine sarcoids. The frequency of natural papillomavirus infections in the horse, together with the occurrence of genital forms of infection, makes this an interesting model. Unfortunately, horses require considerable effort in their upkeep, and most laboratory workers are unfamiliar with this species, although this has not prevented the bovine models from being utilized effectively.
Primate papillomaviruses
Despite the broad host range ofpapillomaviruses , there are only a few reports of the disease in primates. Papillomaviruses have been isolated from the pygmy chimpanzee Pan paniscus (Van Ranst et al., 1992) , 392 the rhesus monkey Macaca mulatta and two species of colobus monkey (Colobuspolykomus and C. guereza; Boever & Kern, 1976; Reszka et al., 1991) .
Of particular interest is the rhesus papillomavirus (RhPV-l). This virus can be transmitted sexually and has been associated with squamous cell carcinoma of the cervix and a carcinoma of the penis (Kloster et al., 1988; Ostrow et al., 1990) . RhPV-l has similarities with the high-risk HPV-16 and -18, being integrated in tumour DNA, and has been detected in rhesus monkeys from several different geographical locations (Ostrow et al., 1995) . The genome has been sequenced, confirming similarities with HPV-16 . Some in vitro work has established cooperation of RhPV-l with cellular oncogenes during transformation ofrat epithelial cells (Schneider et al., 1991) and transforming abilities have been localized to the E5, E6 and E7 ORFs (Ostrow et al., 1993) .
The rhesus monkey is not the only non-human primate in which sexually transmitted papillomavirus infections have been described. Although the colobus monkey papillornaviruses have been associated with cutaneous papillomas (Boever & Kern, 1976; Rangan et al., 1980) , a papilloma from the penis of a colobus monkey was found to contain papillomavirus group-specific antigens, virus particles and papillomavirus DNA, providing a further non-human primate model for venereal papillomavirus-associated diseases . The virus isolated from the penile lesion, C. polykomus papillomavirus type 1 (CgPV-l), had similarities with HPV-16 and -18, and could transform cells. The transformed cells were found to have integrated and partially deleted CgPV-l DNA, indicating parallels with the fate of HPV-16 and -18 in some cervical cancer cell lines . A different isolate from a cutaneous papilloma (c. guereza papillomavirus type 2; CgPV-2) was found to be extrachromosomal (Kloster et al., 1988 ) and a laryngeal carcinoma from a colobus monkey was found to contain nucleotide sequences very closely related to RhPV-l (Kloster et al., 1988) . These lesions obviously indicate the potential for non-human primate models of papillomavirus-induced genital and laryngeal tumours.
A further example of a non-human primate papillomavirus infection is that seen in the pygmy chimpanzee P. paniscus (pygmy chimpanzee papillomavirus type 1; PcPV-l). A papillomavirus was associated with clinical signs similar to those of oral focal epithelial hyperplasia of humans (Van Ranst et al., 1991) . The PcPV-l genome was found to have 85% sequence similarity with that of HPV-13, indicating its potential as a model for HPV-13-associated disease, and was classified along with HPV-6, -11, -43 and -44 (Van Ranst et al., 1992) . Non-human primates are of particular interest as models of disease due to their close taxonomic relationships with humans. However, primate models are expensive, they may present important zoonotic disease risks and their use is associated with important ethical considerations. In the final analysis, no animal disease can be regarded as a totally accurate model of its human counterpart.
Conclusions
Many groups in the pharmaceutical industry are engaged in the development of specific antiviral chemotherapies for papillomavirus infections and as their efforts come to fruition the need for effective in ouro and in vivo assays for these drugs becomes acute. The in uitro systems that are available, including both monolayer and organotypic cultures, provide good screening systems for antivirals directed against the high-risk mucosal viruses. However their value as screens for drugs directed against the lowrisk viruses remains to be evaluated. Conversely the animal models in the dog and rabbit are more closely related to the low-risk HPVs and are good test systems for antivirals against these agents. Nonetheless the extreme host specificity of the papillomaviruses means inevitably that no animal model completely reflects the human situation and in the final analysis, the clinical disease response is the best assay for anti-HPV therapies.
